Irina Ridley - Neuropace Chief Secretary
| NPCE Stock | USD 15.05 0.55 3.79% |
Executive
Irina Ridley is Chief Secretary of Neuropace
| Age | 38 |
| Address | 455 North Bernardo Avenue, Mountain View, CA, United States, 94043 |
| Phone | 650 237 2700 |
| Web | https://www.neuropace.com |
Irina Ridley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Irina Ridley against Neuropace stock is an integral part of due diligence when investing in Neuropace. Irina Ridley insider activity provides valuable insight into whether Neuropace is net buyers or sellers over its current business cycle. Note, Neuropace insiders must abide by specific rules, including filing SEC forms every time they buy or sell Neuropace'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Irina Ridley over a year ago Acquisition by Irina Ridley of 80000 shares of Neuropace subject to Rule 16b-3 | ||
Irina Ridley over a year ago Neuropace exotic insider transaction detected |
Neuropace Management Efficiency
The company has return on total asset (ROA) of (0.1119) % which means that it has lost $0.1119 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6927) %, meaning that it created substantial loss on money invested by shareholders. Neuropace's management efficiency ratios could be used to measure how well Neuropace manages its routine affairs as well as how well it operates its assets and liabilities. As of February 16, 2026, Return On Tangible Assets is expected to decline to -0.27. In addition to that, Return On Capital Employed is expected to decline to -0.33. At present, Neuropace's Debt To Assets are projected to slightly decrease based on the last few years of reporting.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ido Marom | Brainsway | 50 | |
| MD MSc | Delcath Systems | 57 | |
| Vojislav MD | Delcath Systems | 57 | |
| Jeremy JD | Sight Sciences | 56 | |
| Jonelle Burnham | CVRx Inc | 55 | |
| Kenneth JD | Senseonics Holdings Common | 59 | |
| Colleen Hanlon | Brainsway | N/A | |
| Chrystal Jensen | Cerus | 53 | |
| Michael Alfieri | Aldeyra | 61 | |
| Laura Nichols | Aldeyra | N/A | |
| Ralph BSc | Genelux Common | 71 | |
| Alex Huang | Rxsight | N/A | |
| Patrick Cullen | Rxsight | N/A | |
| Jessica Hanover | Cerus | N/A | |
| Oliver Moravcevic | Rxsight | N/A | |
| RN MBA | CVRx Inc | N/A | |
| Reay MD | Sight Sciences | N/A | |
| Nina Mufti | Cerus | N/A | |
| Kelly Mizer | Aldeyra | N/A | |
| Rebecca Williston | Rxsight | N/A | |
| Kenneth Horton | Senseonics Holdings Common | 57 | |
Management Performance
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.11 |
Neuropace Leadership Team
Elected by the shareholders, the Neuropace's board of directors comprises two types of representatives: Neuropace inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuropace. The board's role is to monitor Neuropace's management team and ensure that shareholders' interests are well served. Neuropace's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuropace's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Irina Ridley, Chief Secretary | ||
| Chi Nguyen, VP Marketing | ||
| Kelley Nicholas, Vice Sales | ||
| Michael Favet, CEO Pres | ||
| Katie Keller, Vice Marketing | ||
| Patrick Williams, Chief Officer | ||
| Rebecca Kuhn, CFO Administration | ||
| Martha MD, Chief Officer | ||
| Scott Schaper, Head Relations | ||
| Mark Saxton, VP Sales | ||
| Leah Akin, General Secretary | ||
| Irene Thomas, Vice Resources | ||
| Martha Morrell, Chief Officer | ||
| Dylan John, Chief Development | ||
| Amy Treadwell, Vice Resources | ||
| Julie Hsu, VP Controller | ||
| Andre Marquette, Chief Officer | ||
| Joel Becker, President CEO | ||
| Chris Reese, Senior Sales |
Neuropace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neuropace a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.1) % | ||||
| Current Valuation | 512.45 M | ||||
| Shares Outstanding | 33.31 M | ||||
| Shares Owned By Insiders | 2.71 % | ||||
| Shares Owned By Institutions | 94.34 % | ||||
| Number Of Shares Shorted | 791.61 K | ||||
| Price To Book | 27.07 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.